Unplanned admissions for patients with myeloma in the UK: Low frequency but high costs.
Costs
Elective admissions
Multiple myeloma
Unplanned admissions
Journal
Journal of bone oncology
ISSN: 2212-1366
Titre abrégé: J Bone Oncol
Pays: Netherlands
ID NLM: 101610292
Informations de publication
Date de publication:
Aug 2019
Aug 2019
Historique:
received:
15
03
2019
revised:
31
05
2019
accepted:
04
06
2019
entrez:
22
6
2019
pubmed:
22
6
2019
medline:
22
6
2019
Statut:
epublish
Résumé
Multiple myeloma (MM) is associated with high healthcare resource utilisation and increasing hospitalisation rates. The aim of this study was to characterise the hospital use by patients with MM in the English National Health Service (NHS). Routinely-collected aggregate data about all NHS-funded hospital admissions of patients with MM were analysed. Data were obtained from the English Hospital Episodes Statistics on admissions between 1 April 2014 and 31 March 2018. A total of 754,345 admissions were reported over four years, equivalent to a mean of 188,586 admissions per year. Of the 41,845 patients admitted during this period, 42% were women and 58% men. From the total admissions, 90% were elective and 10% unplanned. Mean annual estimated costs over the period were £46 million for elective and £56 million for unplanned admissions. The number of elective admissions increased by 4.5% with costs increasing 1.5% per year; for unplanned admissions, these figures were 4.1% and 9.0%, respectively. MM is associated with a significant number of hospital admissions and NHS costs. The majority of the hospital admissions are elective, but the highest burden in terms of costs relates to unplanned admissions, with numbers increasing over time.
Sections du résumé
BACKGROUND
BACKGROUND
Multiple myeloma (MM) is associated with high healthcare resource utilisation and increasing hospitalisation rates. The aim of this study was to characterise the hospital use by patients with MM in the English National Health Service (NHS).
METHODS
METHODS
Routinely-collected aggregate data about all NHS-funded hospital admissions of patients with MM were analysed. Data were obtained from the English Hospital Episodes Statistics on admissions between 1 April 2014 and 31 March 2018.
RESULTS
RESULTS
A total of 754,345 admissions were reported over four years, equivalent to a mean of 188,586 admissions per year. Of the 41,845 patients admitted during this period, 42% were women and 58% men. From the total admissions, 90% were elective and 10% unplanned. Mean annual estimated costs over the period were £46 million for elective and £56 million for unplanned admissions. The number of elective admissions increased by 4.5% with costs increasing 1.5% per year; for unplanned admissions, these figures were 4.1% and 9.0%, respectively.
CONCLUSIONS
CONCLUSIONS
MM is associated with a significant number of hospital admissions and NHS costs. The majority of the hospital admissions are elective, but the highest burden in terms of costs relates to unplanned admissions, with numbers increasing over time.
Identifiants
pubmed: 31223562
doi: 10.1016/j.jbo.2019.100243
pii: S2212-1374(19)30028-4
pii: 100243
pmc: PMC6579752
doi:
Types de publication
Journal Article
Langues
eng
Pagination
100243Subventions
Organisme : Medical Research Council
ID : MC_U147585827
Pays : United Kingdom
Organisme : Medical Research Council
ID : MC_U147585819
Pays : United Kingdom
Organisme : Medical Research Council
ID : MC_UP_A620_1014
Pays : United Kingdom
Organisme : Medical Research Council
ID : MC_UU_12011/1
Pays : United Kingdom
Organisme : Medical Research Council
ID : G0400491
Pays : United Kingdom
Organisme : Medical Research Council
ID : MC_U147585824
Pays : United Kingdom
Références
Eur J Haematol. 2005 Feb;74(2):136-43
pubmed: 15654905
Hematology Am Soc Hematol Educ Program. 2005;:353-9
pubmed: 16304403
Blood. 2008 Mar 1;111(5):2516-20
pubmed: 17975015
Hematol Oncol Clin North Am. 2007 Dec;21(6):1231-46, xi
pubmed: 17996596
Neoplasma. 2008;55(4):350-5
pubmed: 18505348
Oncologist. 2010;15(1):6-25
pubmed: 20086168
J Natl Compr Canc Netw. 2010 Feb;8 Suppl 1:S4-S12
pubmed: 20141673
Br J Cancer. 2016 May 24;114(11):1286-92
pubmed: 27070711
Leukemia. 2017 Sep;31(9):1915-1921
pubmed: 28008176
Eur J Haematol. 2017 Aug;99(2):119-132
pubmed: 28306169
Int J Epidemiol. 2017 Aug 1;46(4):1093-1093i
pubmed: 28338941
Eur Urol Focus. 2018 Jul;4(4):586-590
pubmed: 28753845
Leuk Lymphoma. 2018 Apr;59(4):941-949
pubmed: 28805105
Int J Epidemiol. 2017 Dec 1;46(6):1786-1796
pubmed: 29025095
Int J Cancer. 2018 Aug 15;143(4):773-781
pubmed: 29516512
JAMA Oncol. 2018 Sep 1;4(9):1221-1227
pubmed: 29800065